Fast Five Quiz: Breast Cancer Treatment

Pavani Chalasani, MD, MPH

Disclosures

July 12, 2021

An aromatase inhibitor + a CDK4/6 inhibitor is a preferred first-line treatment option to treat patients with metastatic HER2-negative breast cancer who are also postmenopausal, as well as patients who are premenopausal and are also receiving ovarian ablation or suppression.

Steroidal aromatase inactivators, selective ER downregulators, and selective estrogen receptor modulators are all examples of preferred second- and subsequent-line therapy options in this population.

Learn more about the treatment of breast cancer.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....